Legaspi, Brenda C.
HRN: 07-77-92 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/23/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/23/2023
03/29/2023
IV
500mg
Q8hrs
Cholelithiases
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes